NCT03312582

Locally Delivered 1% Metformin Gel in Peri-implantitis

Efficacy of Locally Delivered 1% Metformin Gel in the Treatment of Peri-implantitis in Type2 Diabetes Mellitus Patients: A Randomized Controlled Clinical Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: King Saud University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

This study evaluates the efficacy of 1% local metformin gel in deep periimplant pockets of type 2 diabetes mellitus patients. Half of the participants will receive 1% metformin gel with manual debridement while the other half will receive a placebo with manual debridement.

Detailed description

Metformin is an oral hypoglycemic drug categorized under biguanide and are considered the most efficient agents widely used in the treatment of type 2 diabetes mellitus.The general clinical benefits observed in therapy with MF seem to be greater than expected. They induce osteoblast cells to promote early bone formation through AMP kinase (AMPK) activity. Moreover, in a recent in vitro study, MF facilitated in the proliferation of MG63 osteoblast like cells. Thus, their action in stimulating bone formation has justified their use in the treatment of perimplantitis.

Conditions

• Peri-Implantitis

Interventions

Type	Name	Description
DRUG	1% local metformin gel	After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
PROCEDURE	Placebo

Timeline

• Start date: 2015-03-15
• Primary completion: 2016-08-14
• Completion: 2017-07-24
• First posted: 2017-10-17
• Last updated: 2017-10-17